These findings indicate that abnormal claudin-1 expression promotes tumor progression and drug resistance through interaction with aldo-keto reductase proteins, highlighting both as potential biomarkers and therapeutic targets in pancreatic cancer. This evidence concerns the gene CLDN1 and familial pancreatic carcinoma.